Eur Respir J 2002; 19:765-775
Copyright ©ERS Journals Ltd 2002
European framework for tuberculosis control and elimination in countries with a low incidence
Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group
J.F. Broekmans1,
G.B. Migliori2,
H.L. Rieder3,
J. Lees4,
P. Ruutu5,
R. Loddenkemper6 and
M.C. Raviglione7
1 Royal Netherlands Tuberculosis Association, The Hague, the Netherlands. 2 World Health Organization Collaborating Centre for Control of Tuberculosis and Lung Diseases in Europe, Fondazione Salvatore Maugeri, Clinica del Lavoro e della Riabilitazione, Care and Research Institute, Dept. Pneumonology, Tradate, Italy. 3 Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease, Paris, France. 4 Dept of Health, London, UK. 5 National Public Health Institute, Helsinki, Finland. 6 German Central Committee against Tuberculosis, Berlin, Germany. 7 Communicable Disease Programme, World Health Organization, Geneva, Switzerland
CORRESPONDENCE: G.B. Migliori, WHO Collaborating Centre for Control of Tuberculosis and Lung Diseases, Fondazione Salvatore Maugeri, Clinica del Lavoro e della Riabilitazione, Care and Research Institute, via Roncaccio 16, 21049, Tradate (VA), Italy. Fax: 39 0331829402. E-mail: gbmigliori@fsm.it
Keywords: control, elimination, Europe, new framework, tuberculosis
Received: July 19, 2001
Accepted October 27, 2001
Abstract
As countries approach the elimination phase of tuberculosis, specific problems and challenges emerge, due to the steadily declining incidence in the native population, the gradually increasing importance of the importation of latent tuberculosis infection and tuberculosis from other countries and the emergence of groups at particularly high risk of tuberculosis.
Therefore, a Working Group of the World Health Organization (WHO), the International Union Against Tuberculosis and Lung Disease (IUATLD) and the Royal Netherlands Tuberculosis Association (KNCV) have developed a new framework for low incidence countries based on concepts and definitions consistent with those of previous recommendations from WHO/IUATLD Working Groups.
In low-incidence countries, a broader spectrum of interventions is available and feasible, including: 1) a general approach to tuberculosis which ensures rapid detection and treatment of all the cases and prevention of unnecessary deaths; 2) an overall control strategy aimed at reducing the incidence of tuberculosis infection (risk-group management and prevention of transmission of infection in institutional settings) and 3) a tuberculosis elimination strategy aimed at reducing the prevalence of tuberculosis infection (outbreak management and provision of preventive therapy for specified groups and individuals).
Government and private sector commitment towards elimination, effective case detection among symptomatic individuals together with active case finding in special groups, standard treatment of disease and infection, access to tuberculosis diagnostic and treatment services, prevention (e.g. through screening and bacille Calmette-Guéria immunization in specified groups), surveillance and treatment outcome monitoring are prerequisites to implementing the policy package recommended in this new framework document.
This article has been cited by other articles:

|
 |

|
 |
 
G. B. Migliori and S. Weis
Searching for the Tuberculosis "Needle in the Haystack": Do We Need a New Approach to Find Tuberculosis in Countries with a Low Burden of Tuberculosis?
Am. J. Respir. Crit. Care Med.,
November 15, 2009;
180(10):
916 - 917.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Wallace, J. S. Kammerer, M. F. Iademarco, S. P. Althomsons, C. A. Winston, and T. R. Navin
Increasing Proportions of Advanced Pulmonary Tuberculosis Reported in the United States: Are Delays in Diagnosis on the Rise?
Am. J. Respir. Crit. Care Med.,
November 15, 2009;
180(10):
1016 - 1022.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Neely, H. Maguire, F. Le Brun, A. Davies, D. Gelb, and S. Yates
High rate of transmission among contacts in large London outbreak of isoniazid mono-resistant tuberculosis
J. Public Health Med.,
June 19, 2009;
(2009)
fdp056v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Mor, Y. Lerman, and A. Leventhal
Pre-immigration screening for pulmonary tuberculosis
Eur. Respir. J.,
March 1, 2009;
33(3):
701 - 702.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. R. Steingart, N. Dendukuri, M. Henry, I. Schiller, P. Nahid, P. C. Hopewell, A. Ramsay, M. Pai, and S. Laal
Performance of Purified Antigens for Serodiagnosis of Pulmonary Tuberculosis: a Meta-Analysis
Clin. Vaccine Immunol.,
February 1, 2009;
16(2):
260 - 276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Mor, G. B. Migliori, S. P. Althomsons, R. Loddenkemper, L. Trnka, and M. F. Iademarco
Comparison of tuberculosis surveillance systems in low-incidence industrialised countries
Eur. Respir. J.,
December 1, 2008;
32(6):
1616 - 1624.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. de Vries, H. W. M. Baars, M. M. G. G. Sebek, N. A. H. van Hest, and J. H. Richardus
Transmission Classification Model To Determine Place and Time of Infection of Tuberculosis Cases in an Urban Area
J. Clin. Microbiol.,
December 1, 2008;
46(12):
3924 - 3930.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. H. Bothamley, L. Ditiu, G. B. Migliori, C. Lange, and TBNET contributors
Active case finding of tuberculosis in Europe: a Tuberculosis Network European Trials Group (TBNET) survey
Eur. Respir. J.,
October 1, 2008;
32(4):
1023 - 1030.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Borgen, B. Koster, H. Meijer, V. Kuyvenhoven, M. van der Sande, and F. Cobelens
Evaluation of a large-scale tuberculosis contact investigation in the Netherlands
Eur. Respir. J.,
August 1, 2008;
32(2):
419 - 425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Erkens, E. Slump, M. Kamphorst, S. Keizer, P. J. H. J. van Gerven, R. Bwire, M. Berkel, M. W. Borgdorff, and S. Verver
Coverage and yield of entry and follow-up screening for tuberculosis among new immigrants
Eur. Respir. J.,
July 1, 2008;
32(1):
153 - 161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I C Ditah, M Reacher, C Palmer, J M Watson, J Innes, M E Kruijshaar, H N Luma, and I Abubakar
Monitoring tuberculosis treatment outcome: analysis of national surveillance data from a clinical perspective
Thorax,
May 1, 2008;
63(5):
440 - 446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Diel, P. Wrighton-Smith, and J-P. Zellweger
Cost-effectiveness of interferon-{gamma} release assay testing for the treatment of latent tuberculosis
Eur. Respir. J.,
August 1, 2007;
30(2):
321 - 332.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Inigo, D. Garcia de Viedma, A. Arce, E. Palenque, N. Alonso Rodriguez, E. Rodriguez, M. J. Ruiz Serrano, S. Andres, E. Bouza, and F. Chaves
Analysis of Changes in Recent Tuberculosis Transmission Patterns after a Sharp Increase in Immigration
J. Clin. Microbiol.,
January 1, 2007;
45(1):
63 - 69.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J F Ludvigsson, J Wahlstrom, J Grunewald, A Ekbom, and S M Montgomery
Coeliac disease and risk of tuberculosis: a population based cohort study
Thorax,
January 1, 2007;
62(1):
23 - 28.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Sester, H. Junker, T. Hodapp, A. Schutz, B. Thiele, A. Meyerhans, H. Kohler, and M. Sester
Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy
Nephrol. Dial. Transplant.,
November 1, 2006;
21(11):
3258 - 3268.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. B. Migliori, P. C. Hopewell, F. Blasi, A. Spanevello, and M. C. Raviglione
Improving the TB case management: the International Standards for Tuberculosis care
Eur. Respir. J.,
October 1, 2006;
28(4):
687 - 690.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Wrighton-Smith and J-P. Zellweger
Direct costs of three models for the screening of latent tuberculosis infection
Eur. Respir. J.,
July 1, 2006;
28(1):
45 - 50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T G Connell, N Curtis, S C Ranganathan, and J P Buttery
Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children
Thorax,
July 1, 2006;
61(7):
616 - 620.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Controlling Tuberculosis in the United States
Am. J. Respir. Crit. Care Med.,
November 1, 2005;
172(9):
1169 - 1227.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Shams, S. E. Weis, P. Klucar, A. Lalvani, P. K. Moonan, J. M. Pogoda, K. Ewer, and P. F. Barnes
Enzyme-linked Immunospot and Tuberculin Skin Testing to Detect Latent Tuberculosis Infection
Am. J. Respir. Crit. Care Med.,
November 1, 2005;
172(9):
1161 - 1168.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. A. Kang, H. W. Lee, H. I. Yoon, B. Cho, S. K. Han, Y.-S. Shim, and J.-J. Yim
Discrepancy Between the Tuberculin Skin Test and the Whole-Blood Interferon {gamma} Assay for the Diagnosis of Latent Tuberculosis Infection in an Intermediate Tuberculosis-Burden Country
JAMA,
June 8, 2005;
293(22):
2756 - 2761.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. de Colombani, N. Banatvala, R. Zaleskis, and D. Maher
European framework to decrease the burden of TB/HIV
Eur. Respir. J.,
September 1, 2004;
24(3):
493 - 501.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Cazzadori, B. Allegranzi, A. Scardigli, F. Favari, and E. Concia
Is the Recommendation Not To Use Rifampin Plus Pyrazinamide for Latent Tuberculosis Treatment Always Imperative?
Chest,
August 1, 2004;
126(2):
657 - 658.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Brock, K. Weldingh, T. Lillebaek, F. Follmann, and P. Andersen
Comparison of Tuberculin Skin Test and New Specific Blood Test in Tuberculosis Contacts
Am. J. Respir. Crit. Care Med.,
July 1, 2004;
170(1):
65 - 69.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A Lalvani
Spotting latent infection: the path to better tuberculosis control
Thorax,
November 1, 2003;
58(11):
916 - 918.
[Full Text]
|
 |
|

|
 |

|
 |
 
C. M. Nolan
Isoniazid for Latent Tuberculosis Infection: Approaching 40 and Reaching Its Prime
Am. J. Respir. Crit. Care Med.,
August 15, 2003;
168(4):
412 - 413.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. R. Dahle, P. Sandven, E. Heldal, and D. A. Caugant
Continued Low Rates of Transmission of Mycobacterium tuberculosis in Norway
J. Clin. Microbiol.,
July 1, 2003;
41(7):
2968 - 2973.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Loddenkemper, D. Sagebiel, and A. Brendel
Strategies against multidrug-resistant tuberculosis
Eur. Respir. J.,
July 1, 2002;
20(36_suppl):
66S - 77s.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P.D.O. Davies
A European framework for effective tuberculosis control
Eur. Respir. J.,
April 1, 2002;
19(4):
590 - 592.
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the European Respiratory Society.
|